Risks and benefits of gene therapy.
Noguchi
Philip
P
Food and Drug Administration, Rockville, Md, USA.
D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins / Q000235:genetics; D015870:Gene Expression; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors; D006801:Humans; D060588:LIM Domain Proteins; D018655:Lymphocyte Count; D008667:Metalloproteins / Q000235:genetics; D016254:Mutagenesis, Insertional; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000209:etiology*; D011518:Proto-Oncogene Proteins; D012190:Retroviridae; D016511:Severe Combined Immunodeficiency / Q000628:therapy*; D013601:T-Lymphocytes
D048868:Adaptor Proteins, Signal Transducing; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D011518:Proto-Oncogene Proteins